BMC Immunology最新文献

{"title":"Superiority of pan-immune inflammation value, systemic inflammation index, and CALLY scores prognostic value for mortality of ischemic stroke patients followed in intensive care unit.","authors":"Gülsüm Altuntaş, Rahmet Yıldırım, İsmail Demirel","doi":"10.1186/s12865-025-00730-7","DOIUrl":"10.1186/s12865-025-00730-7","url":null,"abstract":"<p><strong>Aims: </strong>The Inflammatory response plays an important role in the pathophysiology and prognosis of ischemic stroke. Hyperinflammation progresses with aggravation of brain damage and deterioration in clinical status. The study aimed to demonstrate a valuable, easy-to-obtain, and inexpensive parameter for prognostic assessment by comparing the Pan-immune Inflammation Value (PIV), Systemic Immune-Inflammation Index (SII), and CALLY scores in patients with ischemic stroke.</p><p><strong>Methods: </strong>In this retrospective single-center cohort study, the files of patients who were followed up with a diagnosis of ischemic stroke in the tertiary intensive care units. Multivariate regression analysis and receiver operating characteristic curves(ROC) were used to detect the association between PIV, SII, and CALLY on in-hospital mortality and their superiority over each other in predicting mortality in ischemic stroke patients.</p><p><strong>Results: </strong>Of 1,039 patients, 453 died, resulting in an overall survival rate of 56.4%. In the multivariate analysis, high APACHE II scores and low albumin levels remained independent risk factors. ROC curves showed that PIV, SII, and CALLY exhibited good predictive values, with AUCs of 0.921, 0.887, and 0.930 (95% CI: 0.903-0.936, 0.855-0.896, 0.913-0.945; p < 0.001). A pairwise comparison of the data based on AUC values indicated a significant difference between SII and both PIV and CALLY (p < 0.001). In contrast, no significant difference was found between PIV and CALLY (p = 0.385).</p><p><strong>Conclusion: </strong>The PIV, SII, and CALLY indices serve as accessible and reliable prognostic biomarkers that can enhance personalized treatment strategies and improve clinical decision-making in patients with ischemic stroke.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"49"},"PeriodicalIF":2.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12235825/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583029","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Integrated analysis of polytranscriptomics reveals TNFSF ligand genes in pancreatic cancer prognosis and immune regulation.","authors":"Zhaoda Deng, Lincheng Li, Zitong Yang, Guineng Zeng, Rong Liu","doi":"10.1186/s12865-025-00733-4","DOIUrl":"10.1186/s12865-025-00733-4","url":null,"abstract":"<p><p>The tumor necrosis factor (TNF) ligand superfamily plays a critical role in immune regulation and has emerged as a promising target in cancer immunotherapy. By binding to its receptor OX40 (CD134), TNFSF4 promotes the proliferation and survival of T cells and plays an important role in the tumor immune microenvironment, but its role in pancreatic cancer is unclear. This study aimed to investigate the expression patterns and prognostic significance of TNF ligand family members in pancreatic cancer (PC), with a specific focus on TNFSF4. We analyzed single-cell RNA sequencing data from the GSE212966 dataset to assess the expression of TNFSF ligands across immune cell types. TCGA-PAAD bulk RNA-seq data were used for non-negative matrix factorization (NMF) clustering to identify molecular subtypes based on TNFSF ligand expression profiles. Immune infiltration was quantified using single-sample gene set enrichment analysis (ssGSEA), and Kaplan-Meier survival curves were used to compare overall survival (OS) and progression-free survival (PFS) between subtypes. Immunotherapy response prediction was evaluated using tumor mutational burden (TMB), immunophenoscore (IPS), and tumor immune dysfunction and exclusion (TIDE) scores. Gene expression validation was performed using qRT-PCR. TNFSF ligands were predominantly expressed in antigen-presenting cells, particularly B cells and macrophages. NMF clustering identified two molecular subtypes of PC, with cluster 2 associated with significantly better OS and PFS (p < 0.05). TNFSF4, highly enriched in B cells, was found to regulate immune-related pathways such as B cell receptor signaling and cytokine-cytokine receptor interaction, as revealed by KEGG pathway analysis. TNFSF4 expression also correlated with favorable immunotherapy markers, suggesting its potential role as a predictive biomarker. These findings were supported by qRT-PCR validation. This study provides a TNFSF ligand-based molecular classification of pancreatic cancer and highlights the immunoregulatory role of TNFSF4. Its association with patient prognosis and immunotherapy responsiveness suggests potential clinical utility in guiding treatment strategies.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"50"},"PeriodicalIF":2.9,"publicationDate":"2025-07-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12236027/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144583028","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Analysis of the clinical characteristics of poor immunological reconstitution in AIDS patients after long-term antiviral therapy in Xinjiang, China.","authors":"Kejun Pan, Maimaitiaili Wubuli, Tao Zhang, Shan Fan, Xiaobo Lu","doi":"10.1186/s12865-025-00732-5","DOIUrl":"10.1186/s12865-025-00732-5","url":null,"abstract":"","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"48"},"PeriodicalIF":2.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231686/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144564367","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Reference intervals for peripheral blood natural killer cell, monocyte, and dendritic cell subsets in healthy adults from Zhejiang province, China.","authors":"Longyi Zhang, Xuya Chen, Rui Xing, Yan Lu","doi":"10.1186/s12865-025-00731-6","DOIUrl":"10.1186/s12865-025-00731-6","url":null,"abstract":"","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"47"},"PeriodicalIF":2.9,"publicationDate":"2025-07-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12231752/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study.","authors":"W H A van Poecke, N E F Hooi, T K Mossel, M A W Hermans, P L A van Daele, E M Bunnik, Z Brkic, L K Sels, A A H J Thiadens, P M van Hagen, J A M van Laar, S M Rombach","doi":"10.1186/s12865-025-00693-9","DOIUrl":"10.1186/s12865-025-00693-9","url":null,"abstract":"<p><strong>Introduction: </strong>Adalimumab is a monoclonal antibody that is used to treat autoimmune and inflammatory diseases. Biosimilars for adalimumab, including Hyrimoz, have been developed. We aimed to evaluate the effectiveness and adverse effects of Hyrimoz after switching.</p><p><strong>Methods: </strong>The cohort consisted of patients treated with adalimumab at the Clinical Immunology Outpatient Department of the Erasmus Medical Center between February 2021 and February 2023. Data were collected through electronic patient files and questionnaires sent to the patients. The primary outcome was the number of flares after switching to Hyrimoz, compared to a similar period before the switch. The secondary outcomes were reported adverse effects and patient experience using Hyrimoz.</p><p><strong>Results: </strong>A total of 185 patients were eligible for inclusion. There was no significant difference in the occurrence of flares between Humira and Hyrimoz (P = 0.456). Forty-six of the 185 patients reported adverse effects (24.9%). A total of 25/185 (13.5%) patients reported pain during injection, which was the most frequently reported adverse effect. During the course of this study, 60/185 (32.4%) patients discontinued Hyrimoz treatment because of flares (n = 17 [9.2%]), adverse effects (n = 27 [14.6%]), or more subjective complaints (n = 15 [8.1%]) related to the underlying disease. One patient discontinued treatment because of inactive disease.</p><p><strong>Conclusion: </strong>The number of flares before and after switching to Hyrimoz was comparable. However, adverse effects and increased subjective complaints have been reported after switching to this new biosimilar.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"44"},"PeriodicalIF":2.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12224804/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Epidemiology and clinical features of psoriasis in hard-to-treat body locations: a Chinese nationwide population-based study.","authors":"Lingyi Lu, Lu Cao, Fan Jiang, Sihan Wang, Yingzhe Yu, Hua Huang, Bingjiang Lin","doi":"10.1186/s12865-025-00724-5","DOIUrl":"10.1186/s12865-025-00724-5","url":null,"abstract":"<p><strong>Background: </strong>Having psoriasis in hard-to-treat areas, such as the scalp, face, palms, soles, nails, and genitals, can suffer from a reduced quality of life. This study was designed to investigate the prevalence and risk factors of hard-to-treat body locations of psoriasis, and to describe patients' clinical and demographic characteristics, and quality of life impacts.</p><p><strong>Methods: </strong>We conducted a multicenter observational epidemiological study involving over 1000 hospitals in China, enrolling a total of 7032 psoriasis patients. Groups were compared to patients without involvement of hard-to-treat areas.</p><p><strong>Results: </strong>The most frequently affected hard-to-treat area was the scalp (60.01%), followed by the face (22.47%), nails (18.87%), palms or soles (18.23%), genitals or vulvas (12.00%), respectively. Among all patients, 70.71%, 36.65%, 16.30%, 6.48% and 1.45% of patients had involvement of ≥ 1, ≥2, ≥ 3, ≥4 or ≥ 5 hard-to-treat areas. There was a male predominance among patients with involvement of at least one hard-to-treat area(P < 0.001). The smoking rate, BMI (body mass index) and psoriasis family history in patients with at least one hard-to-treat area involvement were significantly higher than those in patients without hard-to-treat area involvement (P < 0.001), especially among patients with nail involvement. With regards to current DLQI (dermatology life quality index), satisfactory rate, and current BSA (body surface area), these findings were all significantly different (P < 0.001) when compared to patients without involvement of a hard-to-treat area. Notably, even in mild-to-moderate psoriasis (BSA < 10), 65.10% of patients showed involvement of ≥ 1 hard-to-treat area, with significant impacts on quality of life (DLQI increase, all P < 0.001) and treatment satisfaction (P < 0.001 vs. non-involved).</p><p><strong>Conclusion: </strong>Psoriasis commonly affects hard-to-treat locations, even in patients with mild to moderate disease (BSA < 10). The disproportionate impact on quality of life (particularly genital/face involvement) and treatment satisfaction underscores the need for: (1) routine assessment of these areas regardless of BSA, and (2) targeted management of modifiable risk factors (smoking, obesity). These findings support incorporating hard-to-treat area evaluation into psoriasis severity assessments and treatment algorithms.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"45"},"PeriodicalIF":2.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12225188/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559117","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Brucellosis novel multi-epitope vaccine design based on in silico analysis focusing on Brucella abortus.","authors":"Houraalsadat Gharazi, Abbas Doosti, Rahman Abdizadeh","doi":"10.1186/s12865-025-00728-1","DOIUrl":"10.1186/s12865-025-00728-1","url":null,"abstract":"<p><p>Brucella is a common kind of bacteria that has the ability to live within cells and may cause diseases that can be transmitted between animals and humans. Current medical therapy struggles to effectively eradicate Brucella. Thus, it is necessary to develop a multi-epitope vaccine (MEV) in order to effectively prevent Brucella infection. To achieve this objective, we used the reverse vaccinology methodology based on omp19 and Bacterial surface antigen (D15). After conducting our research, we successfully identified 2 cytotoxic T lymphocyte (CTL) epitopes, 2 helper T lymphocyte (HTL) epitopes, and 2 linear B cell epitopes from Omp19 and Bacterial surface antigen (D15). These epitopes will be further examined in our study. In order to maintain the proper folding of the protein, we connected GGGS and EAAAK consecutively. Adjuvants are added to the N-terminal of the vaccine peptide to boost its immunogenicity. In order to assess the immunity, stability, protection, and practicality of the final MEV, a construct consisting of 387 amino acids was created by connecting linkers and adjuvants. Furthermore, molecular docking and simulations using molecular dynamics were conducted to confirm the binding strength and durability of the MEV-TLR5. Subsequently, codon adaptation and in silico cloning analyses were conducted to determine the potential codons for expressing the MEV. The findings indicated that the MEV exhibited a significant level of immunogenicity. This work has collectively established a theoretical foundation for the development of a vaccine against Brucella.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"46"},"PeriodicalIF":2.9,"publicationDate":"2025-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12232191/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144559110","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Promoter polymorphisms in the JK*01 W.06 allele associated with the Jk(a + ^w) weak antigen phenotype.","authors":"Shuang Liang, Fan Wu, Renhui Jiang, Tong Liu, Liyan Sun, Rong Tang, Yingnan Dang, Zhihui Deng","doi":"10.1186/s12865-025-00727-2","DOIUrl":"10.1186/s12865-025-00727-2","url":null,"abstract":"","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"43"},"PeriodicalIF":2.9,"publicationDate":"2025-06-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12147333/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144246352","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparative efficacy of preventive vs. therapeutic resveratrol in modulating gut microbiota and alleviating inflammation in DSS-induced colitis.","authors":"Senmei Qin, Zongjing Yang, Jinqing Lei, Qingli Xie, Linsui Jiang, Yuanyuan Fan, Yonggu Luo, Kecong Wei, Wei Luo, Bing Yu","doi":"10.1186/s12865-025-00718-3","DOIUrl":"10.1186/s12865-025-00718-3","url":null,"abstract":"<p><strong>Background: </strong>Inflammatory bowel disease (IBD) management remains challenging due to limited preventive strategies and the low bioavailability of therapeutic agents like resveratrol (RSV). While RSV exhibits anti-inflammatory properties, its preventive potential via gut microbiome modulation remains unexplored.</p><p><strong>Methods: </strong>A murine colitis model was established using 2.5% DSS, with mice randomized into control (CON), DSS, therapeutic RSV treatment (RSV), and preventive RSV treatment (PRE) groups. Clinical outcomes, intestinal barrier integrity, inflammatory cytokines, macrophage polarization, TLR4/NF-κB signaling, and gut microbiota (16S rRNA sequencing) were systematically evaluated.</p><p><strong>Results: </strong>Preventive RSV (PRE) outperformed therapeutic RSV across all metrics. PRE attenuated colitis severity by 51.4% (weight loss, P < 0.001 vs. RSV) and restored mucosal architecture (P = 0.048 vs. DSS). Mechanistically, PRE normalized barrier function via transcriptional (ZO-1: 56.7% of CON; Occludin: 14-fold induction vs. DSS) and protein-level recovery (ZO-1: 96.5% of CON, P = 0.02), suppressed pro-inflammatory cytokines (TNF-α: 80.8%; IL-6: 69.9%; IL-18: >96%, P < 0.001 vs. DSS), and promoted M2 macrophage polarization (CD206: 1.7-fold vs. CON, P = 0.02) through TLR4/NF-κB inhibition (53% TLR4 reduction vs. 15% with RSV, P < 0.001). Despite comparable α-diversity between RSV and PRE, PRE uniquely enriched barrier-protective taxa (Lactococcus, Muribaculum) and restored microbial amino acid biosynthesis. Crucially, PRE's efficacy despite low systemic bioavailability implicated microbiome-mediated \"luminal priming\" as its primary mechanism.</p><p><strong>Conclusions: </strong>This study redefines preventive RSV as a microbial ecosystem engineer that preemptively fortifies the gut against inflammation via microbiome-immune-metabolic crosstalk. By prioritizing ecological prevention over symptom suppression, our findings offer a transformative \"food as medicine\" strategy for IBD, highlighting RSV's potential as a chronotherapeutic agent to reshape clinical paradigms.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"42"},"PeriodicalIF":2.9,"publicationDate":"2025-05-28","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12121039/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144172520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The predictive value of peripheral blood monocytic myeloid-derived suppressor cells for survival and immunotherapy responses in tumor patients.","authors":"Wanying Sheng, Yan Ding, Yuting Su, Jing Hu, Lu Wang, Minjie Guo, Xiao Yuan, Deqiang Wang, Chunhua Dai, Xu Wang","doi":"10.1186/s12865-025-00722-7","DOIUrl":"10.1186/s12865-025-00722-7","url":null,"abstract":"<p><strong>Background and objectives: </strong>The identification of affordable and easily accessible indicators to predict overall survival is important for tumor immunotherapy. Myeloid-derived suppressor cells (MDSCs) are a heterogeneous population of immature myeloid cells, which promote tumor immune escape in the tumor microenvironment (TME). This study aimed to determine whether peripheral blood MDSCs could determine their potential as predictors of survival in tumor patients with immunotherapy.</p><p><strong>Methods: </strong>Flow cytometry was used to detect peripheral blood monocytic myeloid-derived suppressor cells (M-MDSCs) and granulocytic myeloid-derived suppressor cells (G-MDSCs) in 126 patients. Multivariate Cox regression analysis was conducted to examine the associations between peripheral blood MDSCs and patient survival. The receiver operating characteristic (ROC) curve determined the optimal cutoff value for peripheral blood MDSCs and grouped the indicators. The relationship between peripheral blood M-MDSCs and the prognosis and treatment outcome of tumor patients was explored.</p><p><strong>Results: </strong>The proportion of peripheral blood M-MDSCs was associated with the prognosis of patients with tumors, as were tumor metastasis, the red blood cell count, absolute neutrophil count, absolute monocyte count, and BMI. Multivariate Cox regression analysis revealed that M-MDSCs, absolute lymphocyte value, and tumor metastasis were independent risk factors affecting the prognosis of patients with tumors. Detection of peripheral blood M-MDSCs obtained high sensitivity and specificity for tumor diagnosis. Patients with high M-MDSCs percentage demonstrated reduced survival durations and diminished responses to immunotherapy compared to those with low M-MDSCs percentage.</p><p><strong>Conclusions: </strong>Peripheral blood M-MDSCs may be used to predict overall survival and immunotherapy efficacy outcomes. This study provides a putative predictive biomarker for clinicians to choose from to predict tumor patients' survival and the selection of receiving immunotherapy regimens.</p>","PeriodicalId":9040,"journal":{"name":"BMC Immunology","volume":"26 1","pages":"41"},"PeriodicalIF":2.9,"publicationDate":"2025-05-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12102814/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144131988","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}